Literature DB >> 32661125

Vaccination with Secreted Aspartyl Proteinase 2 Protein from Candida parapsilosis Can Enhance Survival of Mice during C. tropicalis-Mediated Systemic Candidiasis.

Manisha Shukla1, Soma Rohatgi2.   

Abstract

The rising incidence of non-albicans Candida species globally, along with the emergence of drug resistance, is a cause for concern. This study investigated the protective efficacy of secreted aspartyl proteinase 2 (Sap2) in systemic C. tropicalis infection. Vaccination with recombinant Sap2 (rSap2) protein from C. parapsilosis enhanced survival of mice compared to rSap2 vaccinations from C. albicans (P = 0.02), C. tropicalis (P = 0.06), and sham immunization (P = 0.04). Compared to sham-immunized mice, the fungal CFU number was significantly reduced in organs of Sap2-parapsilosis-immunized mice. Histopathologically, increased neutrophilic recruitment was observed in Sap2-parapsilosis- and Sap2-tropicalis-immunized mice. Among different rSap2 proteins, Sap2-parapsilosis vaccination induced increased titers of Sap2-specific Ig, IgG, and IgM antibodies, which could bind whole fungus. Between different groups, sera from Sap2-parapsilosis-vaccinated mice exhibited increased C. tropicalis biofilm inhibition ability in vitro and enhanced neutrophil-mediated fungal killing. Passive transfer of anti-Sap2-parapsilosis immune serum in naive mice significantly reduced fungal burdens compared to those in mice receiving anti-sham immune serum. Higher numbers of plasma cells and Candida-binding B cells in Sap2-vaccinated mice suggest a role of B cells during early stages of Sap2-mediated immune response. Additionally, increased levels of Th1/Th2/Th17 cytokines observed in Sap2-parapsilosis-vaccinated mice indicate immunomodulatory properties of Sap2. Epitope analysis performed using identified B-cell epitopes provides a basis to understand differences in immunogenicity observed among Sap2-antigens and can aid the development of a multivalent or multiepitope anti-Candida vaccine(s). In summary, our results suggest that Sap2-parapsilosis vaccination can improve mouse survival during C. tropicalis infection by inducing both humoral and cellular immunity, and higher titers of Sap2-induced antibodies are beneficial during systemic candidiasis.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Candidazzm321990; antibodies; cytokines; fungal infection; immunization; inflammation; vaccine

Mesh:

Substances:

Year:  2020        PMID: 32661125      PMCID: PMC7504944          DOI: 10.1128/IAI.00312-20

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  78 in total

1.  Production of biofilm by Candida and non-Candida spp. isolates causing fungemia: comparison of biomass production and metabolic activity and development of cut-off points.

Authors:  Laura Judith Marcos-Zambrano; Pilar Escribano; Emilio Bouza; Jesús Guinea
Journal:  Int J Med Microbiol       Date:  2014-09-01       Impact factor: 3.473

2.  Hybrid phage displaying SLAQVKYTSASSI induces protection against Candida albicans challenge in BALB/c mice.

Authors:  Yicun Wang; Quanping Su; Shuai Dong; Hongxi Shi; Xiang Gao; Li Wang
Journal:  Hum Vaccin Immunother       Date:  2014-01-21       Impact factor: 3.452

3.  A new staining protocol for detection of murine antibody-secreting plasma cell subsets by flow cytometry.

Authors:  Katharina Pracht; Julia Meinzinger; Patrick Daum; Sebastian R Schulz; Dorothea Reimer; Manuela Hauke; Edith Roth; Dirk Mielenz; Claudia Berek; Joana Côrte-Real; Hans-Martin Jäck; Wolfgang Schuh
Journal:  Eur J Immunol       Date:  2017-07-13       Impact factor: 5.532

4.  Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis.

Authors:  Flavia De Bernardis; Haiqun Liu; Rachel O'Mahony; Roberto La Valle; Silvia Bartollino; Silvia Sandini; Steven Grant; Neil Brewis; Ian Tomlinson; Rachel C Basset; John Holton; Ivan M Roitt; Antonio Cassone
Journal:  J Infect Dis       Date:  2006-11-20       Impact factor: 5.226

5.  Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.

Authors:  M A Pfaller; P R Rhomberg; S A Messer; R N Jones; M Castanheira
Journal:  Diagn Microbiol Infect Dis       Date:  2015-04-29       Impact factor: 2.803

6.  A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities.

Authors:  María D Moragues; Miren J Omaetxebarria; Natalia Elguezabal; María J Sevilla; Stefania Conti; Luciano Polonelli; José Pontón
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

7.  Active and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasis.

Authors:  Guanpingsheng Luo; Ashraf S Ibrahim; Samuel W French; John E Edwards; Yue Fu
Journal:  PLoS One       Date:  2011-10-10       Impact factor: 3.240

8.  Secretory Aspartyl Proteinases Cause Vaginitis and Can Mediate Vaginitis Caused by Candida albicans in Mice.

Authors:  Eva Pericolini; Elena Gabrielli; Mario Amacker; Lydia Kasper; Elena Roselletti; Eugenio Luciano; Samuele Sabbatini; Matthias Kaeser; Christian Moser; Bernhard Hube; Anna Vecchiarelli; Antonio Cassone
Journal:  MBio       Date:  2015-06-02       Impact factor: 7.867

9.  A Novel Small Molecule Inhibitor of Candida albicans Biofilm Formation, Filamentation and Virulence with Low Potential for the Development of Resistance.

Authors:  Christopher G Pierce; Ashok K Chaturvedi; Anna L Lazzell; Alexander T Powell; Stephen P Saville; Stanton F McHardy; Jose L Lopez-Ribot
Journal:  NPJ Biofilms Microbiomes       Date:  2015-08-12       Impact factor: 7.290

Review 10.  Vaccines in the treatment of invasive candidiasis.

Authors:  Xiao-juan Wang; Xue Sui; Lan Yan; Yan Wang; Yong-bing Cao; Yuan-ying Jiang
Journal:  Virulence       Date:  2015-01-06       Impact factor: 5.882

View more
  5 in total

1.  B-Cell Epitope Mapping from Eight Antigens of Candida albicans to Design a Novel Diagnostic Kit: An Immunoinformatics Approach.

Authors:  Farzaneh Vahedi; Younes Ghasemi; Amir Atapour; Kamiar Zomorodian; Maryam Ranjbar; Ahmad Monabati; Navid Nezafat; Amir Savardashtaki
Journal:  Int J Pept Res Ther       Date:  2022-05-27       Impact factor: 2.191

Review 2.  Emerging Antifungal Targets and Strategies.

Authors:  Marija Ivanov; Ana Ćirić; Dejan Stojković
Journal:  Int J Mol Sci       Date:  2022-03-02       Impact factor: 5.923

Review 3.  Vaccines against candidiasis: Status, challenges and emerging opportunity.

Authors:  Satya Ranjan Sahu; Swagata Bose; Manish Singh; Premlata Kumari; Abinash Dutta; Bhabasha Gyanadeep Utkalaja; Shraddheya Kumar Patel; Narottam Acharya
Journal:  Front Cell Infect Microbiol       Date:  2022-08-18       Impact factor: 6.073

4.  Design of a multi-epitope vaccine against the pathogenic fungi Candida tropicalis using an in silico approach.

Authors:  Nahid Akhtar; Arshwinder Singh; Atul Kumar Upadhyay; M Amin-Ul Mannan
Journal:  J Genet Eng Biotechnol       Date:  2022-09-29

5.  Expression and Purification along with Evaluation of Serological Response and Diagnostic Potential of Recombinant Sap2 Protein from C. parapsilosis for Use in Systemic Candidiasis.

Authors:  Manisha Shukla; Pankaj Chandley; Harsimran Kaur; Anup K Ghosh; Shivaprakash M Rudramurthy; Soma Rohatgi
Journal:  J Fungi (Basel)       Date:  2021-11-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.